Microbiome Assisted Tumor Microenvironment: Emerging Target of Breast Cancer |
| |
| Affiliation: | 1. Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, GIS, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India;2. Radiation Biology, UGC-DAE-CSR, Kolkata Centre, Kolkata, India;3. Department of Microbiology and FST, GIS, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India;1. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea;2. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea;3. Department of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea;1. Sydney School of Public Health, University of Sydney, Sydney, Australia;2. The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council, Sydney, New South Wales, Australia;3. Westmead Breast Cancer Institute, Westmead Clinical School, School of Medicine, The University of Sydney, Sydney, Australia;1. Institut Curie, Saint Cloud, Surgical Oncology Department, 35, rue Dailly, 92210 Saint-Cloud, France;2. Versailles St Quentin University, Paris-Saclay University, 78180 Montigny-le-Bretonneux, France;3. Institut Curie, Paris, Department of Medical Oncology, Institut Curie, 26 Rue d''Ulm, 75005 Paris, France;4. Institut Curie Paris, Department of Surgery, Institut Curie, 26 Rue d''Ulm, 75005 Paris, France;5. Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France;6. Seintinelles, 40, rue Rémy-Dumoncel, 75014 Paris, France;1. Department of Oncology, Tays Cancer Center, Tampere University Hospital and Faculty of Medicine and Health Technology, Tampere, FI-33521 Tampere, Finland;2. Departrment of Medicine and Health Technology, University of Tampere, Tampere, Finland, FI-33101 University of Tampere;3. Development and Innovation Center, Tampere University Hospital, Tampere, Finland, FI-33521 Tampere, Finland;1. Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. TurgutNoyan Research and Treatment Center, Adana, Turkey;2. Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana, Turkey |
| |
| Abstract: | The microbiome assisted tumor microenvironment (TME) supports the tumors by modulating multiple mechanisms. Recent studies reported that microbiome dysbiosis is the main culprit of immune suppressive phenotypes of TME. Further, it has been documented that immune suppressive stimulate metastatic phenotype in TME via modulating signaling pathways, cell differentiation, and innate immune response. This review aims at providing comprehensive developments in microbiome and breast TME interface. The combination of microbiome and breast cancer, breast TME and microbiome or microbial dysbiosis, microbiome and risk of breast cancer, microbiome and phytochemicals or anticancer drugs were as used keywords to retrieve literature from PubMed, Google scholar, Scopus, Web of Science from 2015 onwards. Based on the literature, we presented the impact of TME assisted microbiome dysbiosis and estrobolome in breast cancer risk, drug resistance, and antitumor immunity. We have discussed the influence of antibiotics on the breast microbiome. we also presented the possible dietary phytochemicals that target microbiome dysbiosis to restore the tumor suppression immune environment in breast TME. We presented the microbiome as a possible marker for breast cancer diagnosis. This study will help in the identification of microbiome as a novel target and diagnostic markers and phytochemicals and microbiome metabolites for breast cancer treatment. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
